Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

5 Hot Marijuana Stocks as Beer Companies Shop for an Acquisition

By Chris Lau, InvestorPlace Contributor

After taking a pause in its uptrend, marijuana stocks could get a lift again as Molson Coors shops for companies in this sector. Though the sector has yet to prove it is profitable, a buyout will lift nearly all marijuana stocks.

Why Tandem Stock Could Continue Its Rally

By Chris Lau, InvestorPlace Contributor

Tandem stock rocketed to a new high after the company won an FDA approval and two analyst upgrades. At a one billion dollar market cap, the stock still has upside.

Why Gevo, Inc. Stock Soared 262% Yesterday

By Chris Lau, InvestorPlace Contributor

Gevo jumped a mouth-watering 261.82% in a single day. However, looking more closely in the company shows that investors will need to exercise caution.

Can Sprout Pharma’s Latest Revival Really Boost VRX Stock?

By Chris Lau, InvestorPlace Contributor

Sprout Pharma is about to revive the libido pill, Addyi. With the same leadership but autonomy from Valeant Pharma, Sprout could turn the drug into a success story.

Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play

By Chris Lau, InvestorPlace Contributor

Teva Pharmaceuticals is quietly moving higher on the stock market for good reason: worries over pricing and the impact of competition in generics is getting clearer. Teva stock is a great long-term bet.

What to Do After Axovant Sciences Ltd Skyrockets Three-fold in a Month

By Chris Lau, InvestorPlace Contributor

Axovant Sciences soared last week after AXON stock presented AXO-Lenti-PD, a gene therapy product that treats Parkinson's Disease.

As Spinal Stocks Climb Toward Yearly Highs, There’s Still Room for Upside

By Chris Lau, InvestorPlace Contributor

Companies in the medical appliances and equipment market of spines are sharply above yearly lows. Analyst coverage in the spinal stock sector is giving those stocks a temporary boost.

Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason

By Chris Lau, InvestorPlace Contributor

Celgene buying out Agios would make sense but either way the company's work on cellular metabolism and gene deleting is interesting the bulls the most. Agios stock is a good buy on its own merits.

Nektar Therapeutics Stock Is a Buy After a Major Market Misread

By Chris Lau, InvestorPlace Contributor

Sellers dominated the trading action on Nektar stock after its preliminary clinical results. Over-reaction or justified selling? The market simply did not understand the results, hurting the NKTR stock price.

After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall

By Chris Lau, InvestorPlace Contributor

Although Crispr’s gene splicing techniques are revolutionary, the rally in CRSP stock is coming to an end as investors question its valuation.

Load More